| Genotypic Testing for HIV Drug Resistance: Related Resources |
 |
| Content reviewed April 2009 |
 |
|
| | | Related Knowledge Base Chapters | | |
| Journal Articles | |  | HIV-1 genetic diversity and transmitted resistance in health care settings in Maputo, Mozambigue
Bartolo I, Casanovas J, Bastos R, et al. J Acquir Immune Def Syndr. 2009;51:323-31. Includes commentary from the UCSF Institute for Global Health. | | | | Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use
Le T, Chiarella J, Simen BB, et al. PLoS. 2009 Jun;4(6):e6079. | | | | HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
Shafer RW, Schapiro JM. AIDS Rev. 2008 Apr-Jun;10(2):67-84. Review. | | | | Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies
Shafer RW, Rhee SY, Bennett DE. Antivir Ther. 2008;13 Suppl 2:59-68. Review. | | | | Antiretroviral therapy: optimal sequencing of therapy to avoid resistance
Martinez-Cajas JL, Wainberg MA. Drugs. 2008;68(1):43-72. Review. | | | | Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy
Johnson JA, Li JF, Wei X. PLoS Med. 2008 Jul 29;5(7):e158. | |
| |
| Guidelines and Best Practices | | | Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2008 Recommendations of an International AIDS Society-USA Panel
CID, 2008:47. [PDF, 447] See also Update of the Drug Resistance Mutations in HIV-1: December 2008, Top HIV Med. 2008 Dec;16(5):138-45. | | | | World Health Organization/HIVResNet Drug Resistance Laboratory Strategy
Bertagnolio S, Derdelinckx I, Parker M, et al. Antivir Ther. 2008;13 Suppl 2:49-57. April 2008.
A laboratory strategy developed by the WHO and the HIVResNet Laboratory Working Group aimed at assisting countries in the development of protocols, standards, and performance indicators for HIV resistance testing. | | | | Guidance for Industry: Class II Special Controls Guidance Document: In Vitro HIV Drug Resistance Genotype Assay
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Rockville, MD: DHHS; August 2007. | |
| |
| Conference Reports and Proceedings | | |
| Online Books and Chapters | | |
| Clinician Support Tools | | |
| Slide Sets | | |
| Images | | |
| Patient and Community Education | | |
| Links | | |
|
HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2013, Regents of the University of California.